Neuberger Berman Group LLC Karuna Therapeutics, Inc. Transaction History

Neuberger Berman Group LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Nov 14, 2024	BUY	$161.01 - $317.85 $9.42 Million - $18.6 Million	58,503 New	58,503 $18.5 Million
Q4 2023 Feb 09, 2024	BUY	$161.01 - $317.85 $9.21 Million - $18.2 Million	57,215 Added 4442.16%	58,503 $18.5 Million
Q3 2023 Nov 14, 2023	BUY	$164.66 - $218.08 $212,082 - $280,887	1,288 New	1,288 $217,000
Q1 2023 May 12, 2023	BUY	$161.33 - $204.36 $43,075 - $54,564	267 Added 2.68%	10,235 $1.86 Million
Q4 2022 Feb 13, 2023	BUY	$191.53 - $236.82 $32,177 - $39,785	168 Added 1.71%	9,968 $1.96 Million
Q3 2022 Nov 15, 2022	SELL	$123.79 - $277.42 $2.78 Million - $6.23 Million	-22,445 Reduced 69.61%	9,800 $2.21 Million
Q2 2022 Aug 15, 2022	SELL	$93.97 - $143.33 $35,332 - $53,892	-376 Reduced 1.15%	32,245 $4.08 Million
Q1 2022 May 13, 2022	BUY	$98.9 - $132.37 $39,164 - $52,418	396 Added 1.23%	32,621 $4.06 Million
Q4 2021 Feb 11, 2022	SELL	$110.64 - $159.4 $989,121 - $1.43 Million	-8,940 Reduced 21.72%	32,225 $4.1 Million
Q3 2021 Nov 12, 2021	BUY	$101.2 - $125.87 $589,085 - $732,689	5,821 Added 16.47%	41,165 $4.92 Million
Q2 2021 Aug 13, 2021	BUY	$107.45 - $135.95 $3.8 Million - $4.81 Million	35,344 New	35,344 $4.02 Million

332K

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

Get notified when there are updates to the investment portfolio of Neuberger Berman Group LLC, based on Form 13F filings with the SEC.

Stay updated on Neuberger Berman Group LLC with notifications on news.